Poterepatide (HDM1005)
HDM1005 · Huadong Medicine
Long-acting injectable GLP-1/GIP dual agonist in China Phase 3 obesity development. U.S. obesity development has not been confirmed.
Selected study results
HDM1005 · Phase 2Mean body-weight changeBody weight decreased 13.32% · 22 weeks · Phase 2
Mean body-weight change · 22 weeks
Study focus: Weight management
Phase 2 results reported in an ADA 2026 abstract.
Adults with overweight or obesity in China · 4 mg vs placebo · Trial N=243 · Treatment-policy estimand; conference abstract. Results & methods ↗
Conference abstract and sponsor report; China Phase 3 results are not yet available.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Huadong reported that China Phase 3 enrollment is complete and data collection is ongoing; pre-NDA communication was expected in Q4 2026.
Next: China pre-NDA consultation and Phase 3 disclosure; U.S./global obesity development remains unconfirmed.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies1 record
HDM1005 obesity Phase 3
Weight managementChina obesity Phase 3; sponsor reports enrollment complete with follow-up and data collection ongoing.
Phase 2 studies1 record
HDM1005 obesity Phase 2
Weight management22-week obesity study; ADA 2026 abstract reported Phase 2 efficacy.
